Zentrum Fuer Nieren Hochdruck Und Stoffwechselerkrankungen
- Address
- lock Available on a paid plan
Zentrum Fuer Nieren Hochdruck Und Stoffwechselerkrankungen
The Zentrum Fuer Nieren Hochdruck Und Stoffwechselerkrankungen is a specialized research center focusing on kidney diseases, hypertension, and metabolic disorders. This center demonstrates extensive expertise in conducting advanced clinical trials examining novel therapeutic approaches for chronic kidney disease (CKD) and its complications, with particular emphasis on cardiovascular-renal outcomes and innovative pharmacological interventions.
- Advanced CKD management including severe kidney disease, dialysis, and kidney transplant recipients
- Rare glomerular diseases including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy
- Combination therapies targeting kidney function preservation and cardiovascular protection
- Metabolic disorders and obesity-related kidney and cardiovascular complications
The center's research portfolio includes cutting-edge investigations into SGLT2 inhibitors such as dapagliflozin and empagliflozin, novel aldosterone synthase inhibitors like baxdrostat and vicadrostat, and dual receptor antagonists including sparsentan. Their trials emphasize clinically meaningful endpoints including eGFR decline, proteinuria reduction, kidney failure prevention, and cardiovascular mortality, addressing the critical intersection between kidney disease, hypertension, and metabolic health across diverse patient populations from early-stage CKD to advanced kidney disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zentrum Fuer Nieren Hochdruck Und Stoffwechselerkrankungen
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of DMX-200 in Adult Patients with Focal Segmental Glomerulosclerosis Receiving Angiotensin II Receptor Blocker Therapy | Dimerix Bioscience Pty Limited | Phase III | Not Recruiting | Mar 2022 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 5 | Unknown | 2019-02-01 | 2025-12-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.